Organogenesis reports Q3 EPS 9c, consensus (1c)
The Fly

Organogenesis reports Q3 EPS 9c, consensus (1c)

Reports Q3 revenue $115.2M, consensus $108.83M.”Our third quarter results underscore the strength of our portfolio and brand equity as customers select Organogenesis (ORGO) as their trusted partner while they navigate this complex market,” said Gary S. Gillheeney, Sr., President, Chief Executive Officer and Chair of the Board for Organogenesis. “We continue to work with policy and lawmakers to craft a solution that addresses spending while ensuring access to safe and effective therapies for all patients, particularly those who are most vulnerable. We believe a resolution is on the horizon.”

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App